Genzyme Corp. reported promising five-year data from its Phase II extension study of alemtuzumab in relapsing-remitting multiple sclerosis (MS), news that could bode well for CD52-targeting drug as it looks to compete in the estimated $14 billion MS market. (BioWorld Today) Read More
